Femogtyve procent af patienter med APL, behandlet med TRISENOX, har oplevet symptomer svarende til et syndrom, der kaldes retinoinsyre- APL (RA- APL) eller differentieringssyndrom, kendetegnet ved feber, dyspnø, øget vægt, pulmonale infiltrater og pleura - eller perikardieeffusioner, med eller uden leukocytose.
Twenty-five percent of patients with APL treated with TRISENOX have experienced symptoms similar to a syndrome called the retinoic-acid-acute promyelocytic leukaemia (RA-APL) or APL differentiation syndrome, characterised by fever, dyspnoea, weight gain, pulmonary infiltrates and pleural or pericardial effusions, with or without leukocytosis.